Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 133 of the 135 references it cites were found in a registry or an index; 50 of the 139 sources its claims cite were checked for support.

Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy

Open access
Varin, Juliette, Morival, Clément, Maillard, Noémien, Adjali, Oumeya, Cronin, Therese · 2021 · International Journal of Molecular Sciences

Abstract

Gene therapy (GT) for ocular disorders has advanced the most among adeno-associated virus (AAV)-mediated therapies, with one product already approved in the market. The bank of retinal gene mutations carefully compiled over 30 years, the small retinal surface that does not require high clinical vector stocks, and the relatively immune-privileged environment of the eye explain such success. However, adverse effects due to AAV-delivery, though rare in the retina have led to the interruption of clinical trials. Risk mitigation, as the key to safe and efficient GT, has become the focus of ‘bedside-back-to-bench’ studies. Herein, we overview the inflammatory adverse events described in retinal GT trials and analyze which components of the retinal immunological environment might be the most involved in these immune responses, with a focus on the innate immune system composed of microglial surveillance. We consider the factors that can influence inflammation in the retina after GT such as viral sensors in the retinal tissue and CpG content in promoters or transgene sequences. Finally, we consider options to reduce the immunological risk, including dose, modified capsids or exclusion criteria for clinical trials. A better understanding and mitigation of immune risk factors inducing host immunity in AAV-mediated retinal GT is the key to achieving safe and efficient GT.

Overview

CoChat Summary

TL;DR

This review argues that immune responses—especially innate microglial and TLR9-mediated sensing of rAAV DNA/CpG sequences—are key risks for retinal gene therapy and can limit its safety and efficacy. It surveys trial adverse events and mitigation strategies including modified capsids, CpG-depleted/deimmunized vectors, lower doses, immunosuppression, and stricter patient exclusion criteria.

Key findings

  • Retinal gene therapy has advanced with one approved product and about 30 active ocular clinical trials; innate and adaptive immune activation is frequent at doses above 1 × 10^11 vg, though humoral antibody responses to transgene products remain rare.
  • Dose-dependent toxicity is reported: in the DME trial NCT04418427, high-dose intravitreal ADVM-022 caused increased ocular pressure in 5/12 and vision loss in 1/12; in X-linked retinoschisis, all patients injected with 1 × 10^11 vg displayed anterior chamber inflammation around 2 weeks and vitritis after a month, while only one patient at 1 × 10^10 vg and none at 1 × 10^9 vg developed similar adverse events.
  • TLR9/MyD88 is described as the only DNA sensor experimentally proven to trigger rAAV-associated immunity; CpG content varies widely across vector elements (e.g., RF1 11.03% for ITR2, 11.62% for CBA, 10.73% for CAG, 13.83% for HSP, 5.94% for SpCas9, 5.32% for SaCas9). CpG-depleted/deimmunized vectors reduced innate and T cell responses, but in one intraocular study inflammation after 4 × 10^11 vg per eye was only delayed.
  • Mitigation options include modified capsids, evading DNA sensing, decreasing dose, immunosuppression (glucocorticoids, rituximab, proteasome inhibitors, hydroxychloroquine), and stricter exclusion criteria such as NAbs above 1:1000, active ocular inflammation, or a history of severe vascular disease.

Methods

  • Narrative review, not primary research; it synthesizes published retinal rAAV gene therapy trial immune responses and mechanistic literature on ocular immune privilege, microglia, DNA sensors, and vector/patient risk factors.
  • Data include a non-exhaustive Table 1 of retinal GT trials with rAAV vectors and immune responses, and Table 2 calculating RF1 associated with CpG sequences in rAAV vector components (ITRs, promoters, transgenes, supplementary elements).
  • Main analysis is qualitative: it compares trial routes and doses, discusses TLR9/MyD88 and other DNA sensors, and proposes risk-mitigation strategies; no systematic search or meta-analysis is described.

Limitations

  • Stated: Table 1 is non-exhaustive; little information is available on effector T cell involvement in retinal degenerations; it remains open whether viral particles reach the nucleus in immune cells; there is no consensus on optimal immunomodulatory molecules and dosing; retrospective safety data are not always available; and more uniform adverse-event reporting is needed.
  • Evident: as a narrative review, it does not provide new experimental data or quantify effect sizes; the CpG RF1 table is described as not showing direct TLR9 activation risk, which likely depends on CpG-DNA secondary structure.
  • Evident: many cited trial results come from press releases or clinicaltrials.gov and may lack peer-reviewed detail; the review does not perform a systematic risk-of-bias assessment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms222312818

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Retinal immune system. (A) In normal immunological conditions, multiple mechanisms are dedicated to immune tolerance and immune privilege. (1) The blood-retina barrier, which is partly composed by tight junctions (depicted in yellow) between RPE cells, acts as a physical and immune bulwark. It blocks the entry of circulating immune cells inside the retina and prevents antigens from escaping the retina [14,15,16]. (2) The retinal microenvironment, composed of immunoinhibitory and trophic factors secreted by the RPE, Müller glial cells, or astrocytes, promotes cell survival and tolerogenic immune responses (impairment of activated T-cell and APC functions, promotion of T-reg induction, and mitigation of inflammatory processes) [8,17,18,19,20,21,22]. (3) Microglial cells, often described as immune wardens, constitute the bulk of the retinal immune cells. They are found in a resting state in the healthy retina [23,24]. (4) Microglial cells are assisted by the complement system, a few resident macrophages and other retinal cells that perform immune surveillance and can act as APCs: Müller glia, astrocytes, or RPE cells [25,26]. While the immune tolerance mechanism tries to counterbalance inflammation, danger signals in the retina may still result in mild activation of the innate immune system, in a process recently termed para-inflammation [27,28,29]. (B) During stronger challenges, disruption of the immune privilege may occur. Recruitment and activation of circulating or resident immune cells in the retina, potentially including T cells, usually result in a full-fledged immune response and inflammation, causing permanent tissue damage [30,31].
Figure 1 Retinal immune system. (A) In normal immunological conditions, multiple mechanisms are dedicated to immune tolerance and immune privilege. (1) The blood-retina barrier, which is partly composed by tight junctions (depicted in yellow) between RPE cells, acts as a physical and immune bulwark. It blocks the entry of circulating immune cells inside the retina and prevents antigens from escaping the retina [14,15,16]. (2) The retinal microenvironment, composed of immunoinhibitory and trophic factors secreted by the RPE, Müller glial cells, or astrocytes, promotes cell survival and tolerogenic immune responses (impairment of activated T-cell and APC functions, promotion of T-reg induction, and mitigation of inflammatory processes) [8,17,18,19,20,21,22]. (3) Microglial cells, often described as immune wardens, constitute the bulk of the retinal immune cells. They are found in a resting state in the healthy retina [23,24]. (4) Microglial cells are assisted by the complement system, a few resident macrophages and other retinal cells that perform immune surveillance and can act as APCs: Müller glia, astrocytes, or RPE cells [25,26]. While the immune tolerance mechanism tries to counterbalance inflammation, danger signals in the retina may still result in mild activation of the innate immune system, in a process recently termed para-inflammation [27,28,29]. (B) During stronger challenges, disruption of the immune privilege may occur. Recruitment and activation of circulating or resident immune cells in the retina, potentially including T cells, usually result in a full-fledged immune response and inflammation, causing permanent tissue damage [30,31].CC BY · PubMed Central
Figure 2 The central role of microglial cells in the viral vector sensing and induced immune toxicity. Activation of microglial cells after vector viral sensing can lead to pro-inflammatory cytokine release, promoting retinal cell or neuronal death in the context of endangered cells. In turn, cell degeneration may favor microglial activation. ROS: reactive oxygen species; NO: nitric oxide.
Figure 2 The central role of microglial cells in the viral vector sensing and induced immune toxicity. Activation of microglial cells after vector viral sensing can lead to pro-inflammatory cytokine release, promoting retinal cell or neuronal death in the context of endangered cells. In turn, cell degeneration may favor microglial activation. ROS: reactive oxygen species; NO: nitric oxide.CC BY · PubMed Central
Figure 3 Microglia-mediated immune response may be triggered by DNA sensing of therapeutic DNA sequences. Viral vector sensing can occur in diverse compartments of the cell, following endocytosis of therapeutic rAAV particles or phagocytosis of transduced cell debris containing DNA. TLR9 recognizes CpG hypomethylated DNA sequences in the endosome, AIM2, and cGAS recognize dsDNA in the cytosol, and IFI16 recognizes dsDNA mainly in the nucleus. Red dashed circles depict possible DNA sensing. RPE: retinal pigmented epithelium; HC: horizontal cells; BC: bipolar cells; AC: amacrine cells; GC: ganglion cells.
Figure 3 Microglia-mediated immune response may be triggered by DNA sensing of therapeutic DNA sequences. Viral vector sensing can occur in diverse compartments of the cell, following endocytosis of therapeutic rAAV particles or phagocytosis of transduced cell debris containing DNA. TLR9 recognizes CpG hypomethylated DNA sequences in the endosome, AIM2, and cGAS recognize dsDNA in the cytosol, and IFI16 recognizes dsDNA mainly in the nucleus. Red dashed circles depict possible DNA sensing. RPE: retinal pigmented epithelium; HC: horizontal cells; BC: bipolar cells; AC: amacrine cells; GC: ganglion cells.CC BY · PubMed Central

Verification

Claims the paper makes

40 Valid · 10 Not valid · 57 Not checked · 48 Own results and interpretations

80 more claims · 29 with their cited sources checked

Create a free account to see all 155 claims and to verify the 89 references still open.

See all claims — free account
  • It may state two separate claims as one. 53
  • Probably not a substantial claim. 25

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 135 references

Research works printed but not linked: 2

  1. (2021, October 30). Solid Biosciences Announces Clinical Hold on SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy. Available online: https://www.solidbio.com/about/media/press-releases/solid-biosciences-announces-clinical-hold-on-sgt-001-phase-i-ii-clinical-trial-for-duchenne-muscular-dystrophy.
  2. Michaelides, M., Besirli, C., Khan, K., Yang, Y., Wong, C., Sahel, J., Shah, M., Tee, J., Kumaran, N., and Georgiadis, A. (2020, January 13–15). AAV5-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 12-Month Results From a Phase 1/2 Clinical Trial. Proceedings of the AAO Virtual Meeting, Virtual.

Cited by

See all 19

Metadata

Authors
Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T.
Affiliations
  • Inserm (FR)
  • CHU de Nantes, INSERM UMR1089, Translational Gene Therapy for Genetic Diseases, Université de Nantes, F-44200 Nantes, France
Corresponding author
Adjali, Oumeya
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-11-26
Volume
22
Issue
23
Pages
12818
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3215345544
Cited by
19
References
135
Citations by year
2026: 2 · 2025: 9 · 2024: 6 · 2023: 1 · 2022: 1
FWCI
0.29
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
UpGrade Horizon2020 (825825)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
retinal gene therapy, adeno-associated virus vectors, immunogenicity, ocular inflammation, microglia, innate immunity, CpG motifs, dose optimization, exclusion criteria, personalized gene therapy
MeSH terms
Dependovirus, Animals, Genetic Vectors, Humans, Retinal Diseases, Transduction, Genetic, Genetic Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy. https://app.cochat.ai/papers/10.3390/ijms222312818
The paper
Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T. (2021). Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222312818

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.